On Wednesday, Protagonist Therapeutics earned an upgrade to its Relative Strength (RS) Rating, from 70 to 74.
IBD's proprietary rating measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners often have an 80 or higher RS Rating as they launch their biggest climbs. See if Protagonist Therapeutics can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
Protagonist Therapeutics is trying to complete a consolidation with a 48.89 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at -100%.
Protagonist Therapeutics earns the No. 14 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health, Jazz Pharmaceuticals and Novartis ADR are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
